Selection of Patients with Hepatocellular Carcinoma for Sorafenib

View More View Less
  • 1 Memorial Sloan-Kettering Cancer Center, New York, New York

Sorafenib, a multitargeted anti-VEGF receptor and raf kinase inhibitor, was recently approved by the FDA for treating unresectable hepatocellular carcinoma (HCC) based on 2 randomized phase III studies. In addition, a phase II study evaluating sorafenib in patients with HCC and Child-Pugh A and B and a phase I study evaluating sorafenib in patients with organ dysfunction have provided insight about the safety and efficacy of sorafenib in patients with HCC and more advanced cirrhosis, and any difference in outcome based on etiology of HCC. The lack of objective responses observed in the sorafenib arm in the SHARP study also raises practical issues about how to assess response or efficacy of the therapy and thus how long a patient should receive sorafenib. This article addresses these questions on the use of sorafenib in HCC, both in the locally advanced and metastatic settings, in addition to the potential future applications and uses of sorafenib.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Ghassan K. Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10022. E-mail: abou-alg@mskcc.org
  • 1

    U.S. Food and Drug Administration. FDA Approves Sorafenib (Nexavar) for the Treatment of Unresectable Hepatocellular Carcinoma. Available at: http://www.fda.gov/CDER/Offices/OODP/whatsnew/sorafenib.htm. Accessed February 9, 2009.

    • Search Google Scholar
    • Export Citation
  • 2

    Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378390.

  • 3

    Huitzil-Melendez FD, Saltz LB, Song J, et at. Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S) [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 19–21, 2008; Orlando, Florida. Abstract 173.

    • Search Google Scholar
    • Export Citation
  • 4

    Bolondi L, Caspary W, Bennouna J. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 129.

    • Search Google Scholar
    • Export Citation
  • 5

    Cheng AL, Kang YK, Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:2534.

    • Search Google Scholar
    • Export Citation
  • 6

    Abou-Alfa GK, Schwartz L, Ricci S. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:18.

  • 7

    Miller A, Murry DJ, Owzar K. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301 [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3538.

    • Search Google Scholar
    • Export Citation
  • 8

    Olweny CL, Toya T, Katongole-Mbidde E. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975;36:12501257.

    • Search Google Scholar
    • Export Citation
  • 9

    Ihde DC, Kane RC, Cohen MH. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977;61:13851387.

  • 10

    Vogel CL, Bayley AC, Brooker RJ. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 1977;39:19231929.

    • Search Google Scholar
    • Export Citation
  • 11

    Johnson PJ, Williams R, Thomas H. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1978;1:10061009.

  • 12

    Williams R, Melia WM. Liver tumours and their management. Clin Radiol 1980;31:111.

  • 13

    Barbare JC, Ballet F, Petit J. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation.] Bull Cancer 1984;71:442445 [in French].

    • Search Google Scholar
    • Export Citation
  • 14

    Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984;68:487491.

    • Search Google Scholar
    • Export Citation
  • 15

    Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985;56:27512755.

    • Search Google Scholar
    • Export Citation
  • 16

    Yeo W, Mok TS, Zee B. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:15321538.

    • Search Google Scholar
    • Export Citation
  • 17

    Llovet JM, Real MI, Montaña X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:17341739.

    • Search Google Scholar
    • Export Citation
  • 18

    Lo CM, Ngan H, Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:11641171.

    • Search Google Scholar
    • Export Citation
  • 19

    Pelletier G, Roche A, Ink O. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181184.

    • Search Google Scholar
    • Export Citation
  • 20

    Madden MV, Krige JE, Bailey S. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:15981600.

    • Search Google Scholar
    • Export Citation
  • 21

    Group d’Etude et de Traitement de Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:12561261.

    • Search Google Scholar
    • Export Citation
  • 22

    Pelletier G, Ducreux M, Gay F. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998;29:129134.

    • Search Google Scholar
    • Export Citation
  • 23

    Bruix J, Llovet JM, Castells A. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 1998;27:15781583.

    • Search Google Scholar
    • Export Citation
  • 24

    Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 1988;94:453456.

    • Search Google Scholar
    • Export Citation
  • 25

    Cammà C, Schepis F, Orlando A. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:4754.

    • Search Google Scholar
    • Export Citation
  • 26

    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429442.

    • Search Google Scholar
    • Export Citation
  • 27

    Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117136.

    • Search Google Scholar
    • Export Citation
  • 28

    Mathurin P, Rixe O, Carbonell N. Overview of medical treatments in unresectable hepatocellular carcinoma: an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111126.

    • Search Google Scholar
    • Export Citation
  • 29

    Gupta S, Kobayashi S, Phongkitkarun S. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006;41:516521.

    • Search Google Scholar
    • Export Citation
  • 30

    Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8:17431749.

    • Search Google Scholar
    • Export Citation
  • 31

    Giambartolomei S, Covone F, Levrero M. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001;20:26062610.

    • Search Google Scholar
    • Export Citation
  • 32

    Pugh RN, Murray-Lyon IM, Dawson JL. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646649.

  • 33

    Abou-Alfa GK, Amadori D, Santoro A. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis [abstract]? J Clin Oncol 2008;26(Suppl 1):Abstract 4518.

    • Search Google Scholar
    • Export Citation
  • 34

    Furuse J, Ishii H, Nakachi K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159165.

  • 35

    Miller AA, Murry DJ, Owzar K. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; in press.

    • Search Google Scholar
    • Export Citation
  • 36

    Abou-Alfa GK, Zhao B, Capanu M. Tumor necrosis as a correlate for response in subgroup of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib [abstract]. Ann Oncol 2008;19(Suppl 8):Abstract 547P.

    • Search Google Scholar
    • Export Citation
  • 37

    Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698711.

    • Search Google Scholar
    • Export Citation
  • 38

    Abou-Alfa GK, Johnson P, Knox J. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 128.

    • Search Google Scholar
    • Export Citation
  • 39

    Alavi AS, Acevedo L, Min W, Cheresh DA. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 2007;67:27662772.

    • Search Google Scholar
    • Export Citation
  • 40

    Duran I, Hotté SJ, Hirte H. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:48494857.

    • Search Google Scholar
    • Export Citation
  • 41

    Thomas MB, Morris JS, Chadha R. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843850.

    • Search Google Scholar
    • Export Citation
  • 42

    Zhu AX, Sahani DV, di Tomaso E. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4637.

    • Search Google Scholar
    • Export Citation
  • 43

    Faivre SJ, Raymond E, Douillard J. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3546.

    • Search Google Scholar
    • Export Citation
  • 44

    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:14341440.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 267 61 0
PDF Downloads 154 53 0
EPUB Downloads 0 0 0